Pharma Focus Asia

TG ImmunoPharma Receives FDA Approval to Initiate Clinical Trial for TGI-6 Bispecific Antibody

Tuesday, June 20, 2023

TG ImmunoPharma has announced that the FDA has approved the clinical investigation of TGI-6, for the development of breakthrough bispecific antibody.

TGI-6 is a novel antibody developed to target both tumour-associated antigens (TAA) and CD3 molecules. This dual targeting mechanism is designed to enhance anti-tumour responses. By binding to TAAs, which are specific to cancer cells, TGI-6 can directly recognise and attack tumour cells.

TGI-6, a novel therapeutic agent, has been specifically engineered to uphold potent cytotoxic effects while mitigating the potential for cytokine release syndrome (CRS). TGI-6 has demonstrated superior antitumor activity and safety in preclinical studies.

TGI-6 TAA is highly expressed in several solid tumours, including colon cancer, breast cancer, hepatocellular carcinoma, gastric cancer, ovarian cancer, pancreatic cancer and many others. This makes TGI-6 a promising candidate for the treatment of many solid tumours.

Preclinical investigations have showcased the remarkable potential of TGI-6, as it achieved complete regression of tumours in animal models of colourectal cancer following a single administration. TGI-6 is specifically designed to uphold potent cytotoxic activity while mitigating the potential for cytokine release syndrome (CRS).

magazine-slider-imageMFA + MMA 2024CPHI Chine || PMEC China 2024Asia Healthcare Week 2024CPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024ISPE Singapore Affiliate Conference & Exhibition 2024Rehab Expo 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024LogiPharma Asia 2024